Borna Disease Virus Infection Perturbs Energy Metabolites and Amino Acids in Cultured Human Oligodendroglia Cells

Rongzhong Huang1,3,4*, Hongchang Gao2,3, Liang Zhang1,3,4, Jianmin Jia2, Xia Liu1,3,4, Peng Zheng1,3,4, Lihua Ma1,3,4, Wenjuan Li1,3,4, Jing Deng1,3,4, Xiao Wang3,4, Liu Yang3,4, Mingju Wang1,3,4, Peng Xie1,3,4*

1 Department of Neurology, The First Affiliated Hospital, Chongqing Medical University, Chongqing, China, 2 Department of Pharmacy, Wenzhou Medical College, Wenzhou, Zhejiang, China, 3 Chongqing Key Laboratory of Neurobiology, Chongqing, China, 4 Institute of Neuroscience, Chongqing Medical University, Chongqing, China

Abstract

Background: Borna disease virus is a neurotropic, non-cytolytic virus that has been widely employed in neuroscientific research. Previous studies have revealed that metabolic perturbations are associated with Borna disease viral infection. However, the pathophysiological mechanism underlying its mode of action remains unclear.

Methodology: Human oligodendroglia cells infected with the human strain Borna disease virus Hu-H1 and non-infected matched control cells were cultured in vitro. At day 14 post-infection, a proton nuclear magnetic resonance-based metabonomic approach was used to differentiate the metabonomic profiles of 28 independent intracellular samples from Borna disease virus-infected cells (n = 14) and matched control cells (n = 14). Partial least squares discriminant analysis was performed to demonstrate that the whole metabonomic patterns enabled discrimination between the two groups, and further statistical testing was applied to determine which individual metabolites displayed significant differences between the two groups.

Findings: Metabonomic profiling revealed perturbations in 23 metabolites, 19 of which were deemed individually significant: nine energy metabolites (α-glucose, acetate, choline, creatine, formate, myo-inositol, nicotinamide adenine dinucleotide, pyruvate, succinate) and ten amino acids (aspartate, glutamate, glutamine, glycine, histidine, isoleucine, phenylalanine, threonine, tyrosine, valine). Partial least squares discriminant analysis demonstrated that the whole metabolic patterns enabled statistical discrimination between the two groups.

Conclusion: Borna disease viral infection perturbs the metabonomic profiles of several metabolites in human oligodendroglia cells cultured in vitro. The findings suggest that Borna disease virus manipulates the host cell’s metabolic network to support viral replication and proliferation.

Introduction

Borna disease virus (BDV) [1], a neurotropic, non-cytolytic, non-segmented, negative-stranded non-retroviral RNA virus, has been widely employed in neuroscientific research on account of these unique attributes [2]. A previous study by this group has demonstrated that there may be an association between BDV infection and human viral encephalitis [3]. However, the mechanism underlying BDV pathogenesis itself, most notably the influence of BDV infection on host cell metabolism, is not well understood. Previous studies in animal models have demonstrated that BDV infection affects the host’s neuroendocrine systems [4]. Notably, BDV infection perturbs levels of the hormones choleystokinin and somatostatin in vivo. The virus also manipulates cholinergic, GABAergic, and monoaminergic neurotransmitter pathways, as significant alterations in choline acetyltransferase (ChAT), acetylcholinesterase (AChE), glutamic acid decarboxylase (GAD), norepinephrine, and serotonin levels have been reported [5]. Of particular interest are the congruent hippocampal distribution patterns of BDV proteins and the kainite 1 (KA-1) glutamate receptor found in persistently infected rats with learning deficiencies [6,7]. However, the intracellular metabolic alterations associated with BDV infection have not yet been systematically profiled in human cells.
Metabonomics enables the simultaneous quantitative measurement of numerous low molecular weight molecules within a particular sample [8,9]. Metabolic profiling techniques, such as gas/liquid chromatography-mass spectrometry (GC-MS) and nuclear magnetic resonance (NMR) coupled with multivariate statistical modeling, have been used to analyzing the changes in whole metabolic patterns in response to non-physiologic challenges such as viral infection [10,11]. Due to its strong resolution and sensitivity, a NMR-based metabonomic approach instituting high-throughput molecular screening has already demonstrated promising results in metabolite identification and quantification in mammalian cell lines [12].

Cell culture has been successfully applied in metabonomics to enable the investigation of metabolic changes on a cellular and subcellular level. Oligodendrocytes, a widely-used neuronal cell line employed here as a Mycoplasma-free oligodendroglia cell line originally introduced to study BDV and isolate the virus from human white blood cells [13], are a major cellular component of the CNS white matter that play a pivotal role in maintaining neurological function. Oligodendrocytes have been shown to support both natural and artificial infection with several neurotropic NNS RNA viruses (e.g., canine distemper virus [14], measles virus [15], and BDV [16,17]), revealing that oligodendrocytes are a target of these viruses and may be involved in their pathogenic mechanism.

The current study describes the application of a 1H NMR-based metabonomic method in differentiating the metabolic profiles of human oligodendroglia (OL) cells infected with BDV Hu-H1 and matched control cells in vitro. The primary objective of this study is to assess whether metabolic analysis can statistically distinguish the metabolic expression between infected and uninfected cells in order to elucidate BDV’s effect on intracellular metabolic pathways. A secondary objective is to provide information for future studies on the pathogenic mechanisms of BDV, considering the reported integration of BDV genome fragments into mammalian genomes [18,19].

Results

Immunofluorescence Assay

The immunofluorescence assay was applied to stain BDV-specific nucleoprotein p40 at days 3, 5, 7, 9, 12 and 14 post-infection (Fig. 1A). Rapid spread of the virus was observed in tissue culture; 100% of the cells were infected at day 14. The percentage of labeled OL cells was determined through observation of a minimum of 300 randomly selected cells across three independent experiments. BDV infection had no discernible cytopathic effect in these human OL in cell monolayers, as evidenced by phase-contrast microscopy (Fig. 1B and 1C).

Metabonomic Profiling

600 MHz 1D 1H NMR spectra were obtained from both BDV-infected and control OL cells (Fig. 2). The resonance assignments (Fig. 2) were selected based on current literature and verified by 2D 1H–1H COSY and TOCSY spectra. Metabonomic analysis was then applied to statistically differentiate BDV-infected and control OL cells on a whole metabolic pattern basis. First, partial least squares discriminant analysis (PLS-DA) was applied to discriminate between the two groups (n = 28 independent samples; n = 14 per group). The PLS-DA score plots revealed that the BDV-infected OL cells were significantly distinguishable from control OL cells (R²X = 0.821, R²Y = 0.842, Q² = 0.556; Fig. 3). All descriptive parameters were significantly elevated (R²X, R²Y, Q² >0.5), demonstrating that the PLS-DA model was robust (Fig. 3).

PLS-DA loading plot analysis (Fig.4) revealed that 23 key metabolites were primarily responsible for the score plot discrimination between the two groups. As compared to control OL cells, BDV-infected OL cells were characterized by perturbed levels in 11 energy metabolism-related molecules (α-glucose, acetate, choline, creatine, formate, lactate, myo-inositol, N-acetylaspartate (NAA), nicotinamide adenine dinucleotide (NAD+), pyruvate, and succinate) and 12 amino acids (alanine, aspartate, glutamate, glutamine, glycine, histidine, isoleucine, leucine, phenylalanine, threonine, tyrosine, and valine). The spectral resonances assigned to these key metabolites are noted (Fig. 2B). A two-tailed Student’s t-test and non-parametric Mann-Whitney U-test (p-value) were then applied to determine significant differences on a metabolite-by-metabolite basis; levels of 19 of the mentioned 23 metabolites were found to be significantly different between infected and uninfected OL cells after controlling for the false discovery rate (Table 1).

Discussion

BDV is an evolutionary old neurotropic, non-cytolytic RNA virus infecting humans, non-human primates, and other mammalian species. The virus persistently infects brain and blood cells and has integrated its genome fragments into host genomes [11,18,19,20]. BDV’s controversial implication in mood disorders (e.g., bipolar disorder, major depressive disorder) [13] has stimulated worldwide research, but whether and to what extent BDV infection influences the development of any human neuropsychiatric illness remains non-conclusive partly on account of the different diagnostic approaches involved (ELISA, Western blotting) [13,21]. However, given its unique neurotropic and non-lytic properties, BDV is still regarded as an attractive model for investigating brain cell function [22]. Previous studies have demonstrated that BDV infection is associated with perturbations in several metabolic pathways [4,5]. However, the molecular basis of BDV pathogenesis remains largely unknown and requires further elucidation. The current study is the first to use 1H NMR spectroscopy in analyzing BDV-infected intracellular samples.

In this study, a 1H NMR-based metabonomic method was employed to characterize the metabolic changes inside BDV-infected OL cells. A panel of metabolites differentiating BDV-infected and control OL cells were identified at day 14 post-infection; these metabolic “signatures” represent the total sum of intracellular biochemical reactions. Therefore, statistically significant differences in these signatures provide insight into the metabolic pathways affected by BDV; these findings may contribute to a better understanding of BDV’s pathogenic mode of action. One striking observation concerning the PLS-DA score plot (Fig. 3) is the clearly visible separation between BDV-infected OL cells and control OL cells. The dispersion in metabolic profiles among BDV-infected cells is considerably greater than those among healthy control cells in the PLS-DA score plot. This finding may reflect a metabolic “instability” subsequent to BDV infection. As discussed below, significant changes in metabolite levels were observed in i) energy metabolites and ii) amino acids.

Energy Metabolites

In order to drive adenosine triphosphate (ATP) production, α-glucose is glycolytically converted to pyruvate, which is then aerobically catabolized through the TCA cycle/respiratory chain or anaerobically fermented into lactate [23,24,25,26,27] (Fig. 5). Previous studies have demonstrated that several viral infectious
agents disturb both glycolysis and the TCA cycle [11]. In the present study, glucose, myo-inositol, pyruvate, glycine, and acetate levels were all significantly downregulated in BDV-infected OL cells as compared to controls. Moreover, formate, succinate, aspartate, glutamate, and glutamine levels were significantly upregulated in BDV-infected cells as compared to controls [28,29]. As formate is a by-product of formate C-acetyltransferase’s production of acetyl-CoA from pyruvate, it is reasonable to deduce that acetyl-CoA levels (although not directly measurable by the NMR method employed here) were also elevated. Therefore, the lower levels of glycolytic intermediates and their respective by-products in conjunction with the higher levels of acetyl-CoA, TCA intermediates, and their respective by-products indicate a downstream equilibrium shift away from glycolysis and increased carbon flux through the TCA cycle in BDV-infected cells. This shunting toward the TCA cycle is consistent with the decreases in acetate and lactate levels; although the change in lactate was not statistically significant, it is consistent with a shunting away from the anaerobic pathway toward the aerobic pathway in BDV-infected cells [30].

According to Ritter, the replication of any virus requires ATP for the synthesis of macromolecules like proteins or, depending on the virus, DNA or RNA. Additionally, in the case of a lipid-enveloped virus, viral budding requires de novo synthesis of
membrane lipids [31]. Therefore, BDV may be manipulating these pathways to i) produce ATP more efficiently, as the aerobic pathway is approximately 15x more efficient at ATP production than the anaerobic pathway, and/or ii) promote de novo synthesis of membrane lipids, as BDV* particles are enclosed by a 130 nm-diameter lipid envelope that enables budding off the cell surface [32]. As BDV grows to relatively low titers in persistently infected cells with an infectious particle-to-cell ratio of a mere 0.01 to 0.05, ATP requirements for viral particle replication are not particularly demanding relative to most other viruses [33]. However, intranuclear replication, a unique feature of BDV within the order Mononegavirales [2], is associated with frequent ATP-consuming nuclear protein import/export mechanisms. Thus, frequent protein trafficking between the nucleus and cytoplasm, together with the expression of BDV’s N- and P-proteins, may account for the shift to the more energy-efficient aerobic pathway observed in BDV-infected cells.

In addition, this set of metabolic perturbations may have also evolved to promote de novo synthesis of membrane lipids, as has been previously demonstrated for the lipid-enveloped human cytomegalovirus (CMV), [34] through increases in acetyl-CoA and decreases in myo-inositol – a byproduct of membrane-bound phospholipid metabolism – in BDV-infected cells In a previous study, acetyl-CoA has been reported as a carbon contributor to de novo lipid biosynthesis in CMV-infected cells [11]. Moreover, the decreased level of free acetate found in BDV-infected cells accounts for decreased lipolysis/increased liposynthesis, as free acetate is produced in vivo via lipid oxidation. This finding correlates well with the elevated lipid levels previously observed in BDV-infected cells [35]. The downregulation of acetate and myoinositol, combined with the decreased levels of free acetate, likely indicate a more lipid-rich microenvironment conducive to improved viral envelope development and budding. In addition, BDV also depends on glycoprotein-mediated attachment to BDV-susceptible cells; specifically, this glycoprotein localizes to lipid and aids BDV’s entry into cells [32,35]. Thus, BDV’s lipid envelope is important for viral budding as well as glycoprotein-mediated cellular entry – both important elements in viral proliferation. As little research has been done on this specific issue, further investigation is necessary to measure and validate the precise metabolic changes affecting de novo lipid biosynthesis and their relationship to viral proliferation in BDV and other lipid-enveloped viruses.

Amino Acids

Levels of several amino acids were perturbed in BDV-infected cells as compared to controls. Most notably, amino acid metabolic profiling detected significant changes in three non-aromatic amino acids that function as CNS neurotransmitters (aspartate, glutamate, and glycine) and two aromatic amino acids (phenylalanine and tyrosine) that are upstream precursors to two other CNS neurotransmitters, dihydroxyphenylalanine and dopamine [36]. Without regard to the etiopathology of any neurological disease state, this altered amino acid profile is noteworthy in light of previous studies linking other neurotropic viral infections with CNS neurotransmitter dysregulation [37].

In the mammalian CNS, glutamate and aspartate act as the primary excitatory neurotransmitters, while glycine functions as a primary inhibitory neurotransmitter [38,39]. Previous studies in a rat model showed that perturbations in these three neurotransmitters led to over-activation of the N-methyl-D-aspartate (NMDA) receptor, inducing excitotoxicity and neurodegeneration in the hippocampal CA1 region [40,41]. The hippocampal distribution pattern of BDV’s proteins and RNA is restricted to the CA3 region and the dentate gyrus and is absent in the CA1 region. These findings point to the kainate 1 (KA-1) glutamate receptor that has been shown to produce an immunohistologic staining pattern congruent with those of BDV’s N- and P-proteins. This staining pattern, in contrast to the NMDA receptor, are also notably absent in the CA1 region [6]. The current findings are
supported by a previous in vivo neonatal rat brain study that reported higher glutamate levels in BDV-infected subjects, but contrasted on aspartate levels (Fig. 5) [42]. As the current study was performed in vitro, this difference may be explained by a different metabolic processing of aspartate in vivo.

Both phenylalanine and tyrosine levels were found to be elevated in BDV-infected cells as compared to controls. A previous study, employing a high performance liquid chromatography (HPLC)-based metabolomic approach, found that the CNS neurotransmitters dihydroxyphenylalanine and dopamine were significantly upregulated in various brain regions of a BDV-infected rat model [3]. Although not measured in this in vitro study, the upregulation in dihydroxyphenylalanine and dopamine found in the previous in vivo work may be related to the intracellular upregulation of phenylalanine and tyrosine found here. Further investigation is required to shed light on the relationships between BDV infection, the foregoing neurotransmitters, their receptors, and their respective regulatory pathways, particularly with respect to these pathways’ possible interactions with BDV proteins.

Conclusion

In the current study, a $^3$H NMR-based metabolomic method was applied to differentiate the metabolic profiles of human strain BDV Hu-H1-infected human oligodendroglia cells and matched control cells in vitro. Comparative metabolomic profiling revealed statistically significant perturbations in key metabolites associated with amino acids and energy-associated pathway. BDV may be manipulating the host cell’s metabolic network to support viral replication and proliferation through better enabling intracellular trafficking, viral protein expression, and de novo lipid synthesis. However, further studies are required to validate this assertion. Through elucidating the intracellular metabolic changes incident to BDV infection in vitro, this study also provides direction for future exploration on the pathogenic mechanism of BDV infection in vivo.

Materials and Methods

Materials

Human OL cells (a cell line derived from fetal human oligodendrocytes), the BDV Hu-H1 strain (passages 75 and 76 in OL cells) [13] and BDV-specific nucleoprotein p40 monoclonal antibody [43] were kindly supplied by Hanns Ludwig (Free University of Berlin, Germany). The virus strain BDV Hu-H1 is one out of the first three human strains all of which are differing to the genetic profile of the laboratory reference strains V and

Table 1. 23 Key Metabolites Differentiating BDV-infected and Control OL Cells Derived from the PLS-DA Model.

| Metabolite      | Chemical Shift (ppm) | Relative Peak Intensity (x 10^-5) | Fold Δ | P-value | Q-value |
|-----------------|----------------------|----------------------------------|--------|---------|---------|
|                  | Control OL cells     | BDV-infected OL cells             |        |         |         |
| Valine          | 1.061-1.032          | 43 ± 3.5                         | 79 ± 4.6 | 1.84 †  | 7.98E-19d | 1.84E-17 |
| Tyrosine        | 6.913-6.885          | 11 ± 4.3                         | 28 ± 1.7 | 2.55 †  | 3.48E-13d | 4.00E-12 |
| Phenylalanine   | 7.351-7.312          | 11 ± 2.7                         | 20 ± 0.9 | 1.82 †  | 1.10E-11d | 8.42E-11 |
| Pyruvate        | 2.411-2.397          | 13 ± 2.0                         | 7 ± 0.5  | 0.54 ‡  | 2.33E-10d | 1.07E-09 |
| Threonine       | 3.596-3.578          | 16 ± 4.1                         | 28 ± 2.1 | 1.75 †  | 2.24E-10d | 1.29E-09 |
| Creatine        | 3.050-3.032          | 29 ± 9.1                         | 54 ± 3.7 | 1.86 †  | 4.65E-10d | 1.71E-09 |
| Acetate         | 1.926-1.914          | 27 ± 9.2                         | 13 ± 1.3 | 0.48 ‡  | 3.08E-06d | 1.01E-05 |
| Glutamate       | 2.392-2.333          | 56 ± 22.2                        | 177 ± 11.9 | 3.16 †  | 6.70E-06c | 1.71E-05 |
| Isoleucine      | 1.027-1.005          | 41 ± 4.1                         | 73 ± 4.5 | 1.78 †  | 6.70E-06c | 1.93E-05 |
| NADH           | 9.171-9.146          | 7 ± 3.2                          | 13 ± 1.5 | 1.86 †  | 1.03E-05c | 2.15E-05 |
| Choline         | 3.235-3.218          | 19 ± 5.2                         | 38 ± 8.9 | 2.00 †  | 1.03E-05c | 2.37E-05 |
| Glycine         | 3.563-3.550          | 21 ± 9.1                         | 12 ± 1.3 | 0.57 ‡  | 1.57E-05c | 3.00E-05 |
| Myo-inositol    | 3.550-3.517          | 86 ± 23.2                        | 56 ± 7.9 | 0.65 ‡  | 1.14E-04c | 1.87E-04 |
| Glutamine       | 2.479-2.422          | 70 ± 24.3                        | 123 ± 4.0 | 1.76 †  | 1.14E-04c | 2.01E-04 |
| Histidine       | 7.688-7.676          | 57 ± 45.6                        | 13 ± 2.8 | 0.23 ‡  | 1.98E-04c | 3.03E-04 |
| Formate         | 8.452-8.430          | 8 ± 3.9                         | 13 ± 1.4 | 1.63 †  | 5.69E-04c | 8.18E-04 |
| α-Glucose       | 5.247-5.223          | 15 ± 16.5                       | 7 ± 4.1  | 0.47 ‡  | 7.70E-03c | 9.84E-03 |
| Aspartate       | 2.818-2.794          | 18 ± 9.9                        | 20 ± 2.3 | 1.11 †  | 7.70E-03c | 1.04E-02 |
| Succinate       | 2.417-2.411          | 5 ± 0.5                         | 6 ± 0.4  | 1.20 †  | 3.87E-02c | 4.68E-02 |
| Lactate         | 1.350-1.315          | 187 ± 45.0                      | 166 ± 10.9 | 0.89 ‡  | 5.36E-02c | 6.17E-02 |
| Leucine         | 0.950-0.924          | 74 ± 13.1                        | 69 ± 4.1 | 0.93 ‡  | 3.12E-01c | 3.26E-01 |
| Alanine         | 1.496-1.461          | 35 ± 8.7                        | 54 ± 4.4 | 1.54 †  | 3.31E-01c | 3.31E-01 |
| NAA              | 2.052-2.014          | 22 ± 12.8                       | 24 ± 1.8 | 1.09 †  | 3.12E-01c | 3.41E-01 |

Note: The 19 individually significant differential metabolites (p,q<0.05) are bolded for emphasis.

* NAA: N-acetylaspartate, NAD: Nicotinamide adenine dinucleotide.

**Values expressed as means ± SD’s.

*Non-parametric Mann-Whitney U test.

*Student t-test.

*Q-values were calculated by the Benjamini-Hochberg method.

doi:10.1371/journal.pone.0044665.t001
Figure 4. PLS-DA loading plot demonstrating discrimination of 23 key metabolites between BDV-infected OL cells and control OL cells.
doi:10.1371/journal.pone.0044665.g004

Figure 5. Key metabolites of energy production pathway. Red indicates upregulation; green indicates downregulation.
doi:10.1371/journal.pone.0044665.g005
C6BV [44]. Dulbecco’s Modified Eagle’s Medium (DMEM), fetal bovine serum (FBS), penicillin-streptomycin solution (10,000 unit/ml penicillin, 10,000 μg/ml streptomycin), L-glutamine, Phosphate Buffer Saline (PBS) (1×) and 0.25% trypsin-EDTA (1×) were purchased from Hyclone. Ultrapure water was prepared through the Millipore MilliQ purification system. Analytical grade methanol, chloroform and methanal were purchased from the Chongqing Chuandong Chemical (Group) Co., Ltd. Previous basic descriptions on how to grow, titrate, and immunostain BDV infected cells and to prepare virus stocks are adapted as described below.

OL Cell Cultivation

A human OL cell line infected with BDV Hu-H1 strain was grown in DMEM with 10% FBS. The cells were cultured in 10-cm dishes within a humidified incubator (5% CO2, 37°C), and were passaged when they reached 90% confluence by trypsinization. Briefly, the passaging method involved washing the cell monolayer twice with 5.0 ml of PBS (1×) followed by a 2.0 ml trypsin rinse. Thereafter, the cells were incubated at 37°C for 1 min to allow cell detachment. Then, an equal volume of fresh growth medium was added to suspend the detached cells in solution as well as to stop trypsin action. The resultant suspension was split into portions for further subculturing.

BDV Hu Strain Solution Preparation

The cells were sub-cultured into 20 separate 10-cm dishes. When all dishes reached 95% confluence, cells were washed twice with 5.0 ml serum-free DMEM followed by trypsin digestion for 1 min at 37°C. The trypsin was decanted, and 2.0 ml serum-free DMEM was added to each dish to suspend the detached cells in solution. Then, the cell solution was frozen (−80°C) and thawed (25°C) for three consecutive cycles, transferred to 15 ml centrifuge tubes and centrifuged at 3000 rpm for 10 min. The supernatant (containing infectious viral particles) was used as the stock viral solution, and the debris at the bottom of the tube (containing cell matter) was discarded.

BDV Titration

A 96-well plate (Costar) was coated with 50 μl poly-lysine per well for 30 min followed by seeding with 3×10^5 cells per well. Eight hours post-adherence, the medium was removed and 20 μl viral solution was added to each well. The viral solution was serially diluted ten-fold for 5 times, and each concentration level had four replicates. The cells were cultured for seven days in DMEM-2% FBS, during which the cell medium was replaced twice with 5.0 ml PBS (1×) and an exponential line-broadening function of 0.3 Hz was performed in a Bruker AVANCE III 600 spectrometer operating at 600.13 MHz 1H frequency and equipped with a triple resonance probe. Standard one-dimensional (1-D) single-pulse spectra were acquired at 298 K using a 90° flip angle with a spectral width of 12000 Hz and 32 K data points. The acquisition time was 2.66 s per scan, and an additional 8 s relaxation delay (including a 2 s water signal resaturation) was used to ensure full relaxation. The total number of scans was 512. The free induction decay (FID) was zero-filled to 64 K, and an exponential line-broadening function of 0.3 Hz was applied to the FID prior to Fourier transformation. All spectra were phase and baseline corrected and referenced to the methyl peak of lactate (CH3, δ1.33) using the software package Topspin (v2.1 p44, Bruker Biospin, Germany).

BDV Infection of OL Cells

Non-infected human OL cells were subcultured in 28 separate 10-cm dishes. 14 dishes were infected with BDV (stock solution of OL cells infected with BDV Hu-H1 as above) at a multiplicity of infection (MOI) of 1.0. Specifically, the cells were washed twice with serum-free DMEM before 800 μl of stock viral solution was added into each dish. The cells were then stored in a humidified incubator (5% CO2, 37°C) for two hours, with gentle shaking for 15 min. Excess virus was removed by washing with 5 ml of serum-free DMEM before bathing the cells in 10 ml of culture medium (10% FBS in DMEM). The remaining 14 dishes were maintained as uninfected control OL cells. Both cell lines were then incubated under the same conditions for the remainder of the study.

Immunofluorescence Assay

Both BDV-infected and control OL cells were grown on six-well dishes for 30 min at room temperature with 4% paraformaldehyde followed by permeabilization for 5 min in 0.4% Triton X-100. Thereafter, both lines were rinsed with PBS and blocked with 5% (w/v) skimmed milk solution for one hour at 37°C. Overnight incubation with anti-BDV-specific p40 antigen primary monoclonal antibody [43] at 4°C was followed by one hour incubation with secondary antibodies at room temperature. After three PBS washes, immunofluorescence was detected by using a phase-contrast microscopy.

Metabolite Extraction

On day 14 post-infection, cells were washed twice with 5.0 ml serum-free DMEM followed by trypsin digestion for 1 min at 37°C. The trypsin was decanted, and 2.0 ml serum-free DMEM was added to each dish to suspend the detached cells in solution. Then, the cell solution was transferred to 15 ml centrifuge tubes and centrifuged at 3000 rpm for 10 min. The supernatant was discarded, and the remaining cell pellets stored at 4°C. Analytical grade methanol and chloroform in a 2:1 ratio (v/v; 250 μl/cell pellet) at 4°C were added to the cell pellets. The cell pellet-solvent mixture was sonicated. After approximately 15 min in contact with the first solvents, chloroform and distilled water were added to the samples in a 1:1 ratio (250 μl/cell pellet) to form an emulsion. The samples were then centrifuged at 13000 rpm for 20 min. The supernatant was collected, lyophilized, and stored at −80°C for later 1H NMR spectroscopic analysis.

1H NMR Spectroscopy

The lyophilized samples were reconstituted with 600 μl D2O and centrifuged at 12000 rpm for 10 min at 4°C; then, 550 μl aliquots of the supernatant were pipetted into 5 mm NMR tubes for 1H NMR experiments. All NMR readings were performed in a Bruker AVANCE III 600 spectrometer operating at 600.13 MHz 1H frequency and equipped with a triple resonance probe. Standard one-dimensional (1-D) single-pulse spectra were acquired at 298 K using a 90° flip angle with a spectral width of 12000 Hz and 32 K data points. The acquisition time was 2.66 s per scan, and an additional 8 s relaxation delay (including a 2 s water signal resaturation) was used to ensure full relaxation. The total number of scans was 512. The free induction decay (FID) was zero-filled to 64 K, and an exponential line-broadening function of 0.3 Hz was applied to the FID prior to Fourier transformation. All spectra were phase and baseline corrected and referenced to the methyl peak of lactate (CH3, δ1.33) using the software package Topspin (v2.1 p44, Bruker Biospin, Germany).

Chemometric Analysis

Using Topspin, all spectra were divided into 1100 integrated regions of equal width (0.01 ppm “buckets”) corresponding to the spectral region of δ10.0 to δ-1.0. The region of δ5.1 to δ4.3 was set to a zero integral to eliminate the variation produced by both water resonance suppression and partial cross-saturation urca resonance. The remaining spectral segments of each NMR spectrum were normalized to the total integral of the spectral area on a sample-by-sample basis to partially compensate for the minor differences in metabolite concentrations across samples within each group. Chemometric analysis on the data sets was performed using the software package SIMCA-P+ (v12.0.1, Umetrics AB, Umea, Sweden).
Statistical and Network Analysis

The main metabolites responsible for class discrimination were manually calculated by peak integration. The Wilk-Shapiro test was performed to determine normality. For parameters of normal distribution, the independent sample t-test was used to find significantly differentiated metabolites. For the data that did not achieve normality, the non-parametric Mann-Whitney U-test test was used. The Benjamini-Hochberg method (q-value) was conducted on the relative peak intensity data to control for false discovery [43]. A p-value and q-value ≤0.05 were considered to be statistically significant. Compounds were identified based on known chemical shifts published in online databases. The Human Metabolome Database (HMDB [23,46] and the BioMagResBank (BMRB) [25]) were used for the NMR spectral data. The differential compounds and their respective fold changes were then inputted into the KEGG and Metacore (GeneGo) databases for network analysis.

Acknowledgments

We sincerely thank Professor Hans Ludwig, AG Bornavirus infections at the Free University of Berlin, Germany, for providing the OL cell line, the BDV Hu-H1 strain and the anti-p40 monoclonal antibody. We are particularly grateful to Dr. Liv Bode, Robert Koch Institute, Berlin, Germany, for thoroughly revising the virology and proofreading of the manuscript, as well as to Hanns Ludwig for many helpful comments. We also thank Dr. N.D. Melgiri for his assistance in editing and proofreading the manuscript.

Author Contributions

Conceived and designed the experiments: PX RZH LZ. Performed the experiments: HCG RZH MJL WJL. Analyzed the data: XW RZH PZ XL. Contributed reagents/materials/analysis tools: LZ JD LY MJW. Wrote the paper: RZH PX LZ.

References

1. Ludwig H, Bode L, Gosztonyi G (1988) Borna disease: a persistent virus infection of the central nervous system. Prog Med Virol 33: 107–131.
2. de la Torre JC, Bode L, Carbone KM, Dietzschold B, Basta K, et al. (2000) Family Bornaviridae. In: Virus taxonomy. (MHV van Regenmortel, CM Faquet, DHL Bishop eds.), London: Academic Press, 531–538.
3. Li Q, Wang Z, Zhu D, Xu M, Chen X, et al. (2009) Detection and analysis of Bornavirus infection in Chinese patients with neurological disorders. Eur J Neurol 16: 399–403.
4. Solbrig MV, Kooib GF (2003) Neuropharmacological sequelae of persistent CNS viral infections: lessons from Bornavirus disease. PharmacoBio Behav 74: 727–787.
5. Pletnikov MV, Rubin SA, Schwartz GJ, Carbone KM, Moran TH (2000) Effects of neonatal rat Bornavirus disease (BDV) infection on the postnatal development of the brain monosynaptic systems. Brain Res Dev Brain Res 119: 179–185.
6. Gosztonyi G, Ludwig H (2001) Interactions of viral proteins with neurotransmitter receptors may protect or destroy neurons. Curr Top Microbiol Immunol 253: 121–144.
7. Dittrich W, Bode L, Ludwig H, Kao M, Schneider K (1989) Learning deficiencies in Borna disease-infected but clinically healthy rats. Biol Psychiatry 26: 818–829.
8. Beckert O, Kuen HC, Ebbels TM, Bundy J, Holmes E, et al. (2007) Metabolic profiling, metabolic and metabolic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat Protoc 2: 2692–2703.
9. Nicholos JK, Lijung JC, Holmes E (1999) ‘Metabonomics’: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobio- tec 30: 1111–1119.
10. Steinkopf D, Sigrist M, Evers D, Dietzschold B, Basta K, et al. (2010) Direct detection of diverse metabolic changes in virally transformed and tax-expressing cells by mass spectrometry. PLoS One 5: e12590.
11. Munger J, Bajad SU, Coller HA, Shenk T, Rabinowitz JD (2006) Dynamics of NMDA receptor-mediated responses in the rat visual cortex. Brain Res 1130: 100–103.
12. Akhtar SN, Singh RK, Jadegoud Y, Dhole TN, Ayyagari A, et al. (2007) In vitro (1H) NMR studies of RD human kidney cancer cells with echovirus 11. NMR Biomed 20: 422–428.
13. Bode L, Durwald V, Rantam FA, Ferszt R, Ludwig H (1996) First isolates of infectious human Bornavirus disease from patients with mood disorders. Mol Psychiatry 1: 200–202.
14. Muller CF, Fazakerley GS, Beck K, Vandenvelde M, Zurbriggen A (1995) Studies on the cellular metabolism during human cytomegalovirus infection. Eur J Biochem 234: 1057–1065.
15. Ionasescu V, Lijung JC, Holmes E, et al. (2007) Metabolic profiling of Borna disease-infected human OL cells by NMR. J Cereb Blood Flow Metab 15: 12–25.
16. Mason GF, Gruber RP, Rohman DL, Behar KL, Shulman RG, et al. (1995) Simultaneous determination of the rates of the TCA cycle, glucose utilization, alpha-ketoglutarate/glutamate exchange, and glutamine synthesis in human brain by NMR. J Cereb Blood Flow Metab 15: 12–25.
17. Pauli G, Ludwig H (1985) Increase of virus yields and releases of Borna disease virus from infected cells. Virus Res 2: e132.
18. Alkhatr SN, Singh RK, Jadeod Y, Dhole TN, Ayyagari A, et al. (2007) In vitro (1H) NMR studies of RD human kidney cancer cells with echovirus 11. NMR Biomed 20: 422–428.
19. Muller CF, Fazakerley GS, Beck K, Vandenvelde M, Zurbriggen A (1995) Studies on the cellular metabolism during human cytomegalovirus infection. Eur J Biochem 234: 1057–1065.
20. Bode L, Ludwig H (2003) Bornavirus disease infection, a human mental-health risk. Clin Microbiol Rev 16: 534–545.
21. Hornig M, Brieser T, Licinio J, Khashabz FR, Abshuler LL, et al. (2012) Absence of evidence for bornavirus infection in schizophrenia, bipolar disorder and major depressive disorder. Mol Psychiatry 17: 486–493.
22. Hornig M, Solbrig M, Horschli N, Weissenbock H, Lipkin WI (2001) Borna virus disease infection of adult and neonatal rats: models for neuropsychiatric disease. Curr Top Microbiol Immunol 253: 157–177.
23. Utrilla J, Goss G, Martinez A (2009) ATP limitation in a pyruvate formate lyase mutant of Escherichia coli MG1655 increases glycolytic flux to D-lactate. J Ind Microbiol Biotechnol 36: 1057–1062.
24. Feron O (2009) Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells. Radiother Oncol 92: 329–333.
25. Schurr A, Payne RS (2007) Lactate, not pyruvate, is neuronal aerobic glycolysis end product: an in vitro electrophysiological study. Neuroscience 147: 613–619.
26. Fernie AR, Cazzani F, Swedlow JI (2004) Respiratory metabolism: glycolysis, the TCA cycle and mitochondrial electron transport. Curr Opin Plant Biol 7: 234–263.
27. Tilton WM, Seaman C, Carriere D, Pommel S (1991) Regulation of glycolysis in the erythrocyte: role of the lactate/pyruvate and NAD/NADH ratios. J Lab Clin Med 118: 146–152.
28. Mason GF, Gruber R, Rohman DL, Behar KL, Shulman RG, et al. (1995) Simultaneous determination of the rates of the TCA cycle, glucose utilization, alpha-ketoglutarate/glutamate exchange, and glutamine synthesis in human brain by NMR. J Cereb Blood Flow Metab 15: 12–25.
29. Rich PR (2005) The molecular machinery of Kellin’s respiratory chain. Biochem Soc Trans 33: 1095–1105.
30. Ritter JB, Wald AS, Freund S, Genzel Y, Reichl U (2010) Metabolic effects of influenza virus infection in cultured animal cells: Intra- and extracellular metabolite profiling. BMC Syst Biol 4: 61.
31. Kohno T, Goto T, Takasaki T, Morita C, Nakaya T, et al. (1999) Fine structure and morphogenesis of Borna disease virus. J Virol 73: 760–766.
32. Feron O (2009) Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells. Radiother Oncol 92: 329–333.
33. Pauli G, Ludwig H (1985) Increase of virus yields and releases of Borna disease virus from infected cells. Virus Res 2: 29–33.
34. Lau ST, Sharif-Freling R, Ivanova P, Milea SB, Myers DS, et al. (2011) Symbiotic vescicle-like lipidome of human cytomegalovirus virions reveals a role for SNARE machinery in virion egress. Proc Natl Acad Sci U S A 108: 1269–1267.
35. Clemente R, de Parsavai A, Perez M, de la Torre JC (2009) Borna disease virus requires cholesterol in both cellular membrane and viral envelope for efficient cell entry. J Virol 83: 2655–2662.
36. Lou HC (1994) Dopamine precursors and brain function in phenylalanine hydroxylase deficiency. Acta Paediatr Suppl 407: 16–81.
37. Zhang CX, Ouyai H, He M, Bu X, Wen Y, et al. (2005) Neuronal activity regulates viral replication of herpes simplex virus type 1 in the nervous system. J Neurovirol 11: 256–264.
38. Aguilar E, Tena-Sempere M, Puillana I (2005) Role of excitatory amino acids in the control of growth hormone secretion. Endocrine 28: 295–302.
39. Legendre P (2001) The glycinergic inhibitory synapse. Cell Mol Life Sci 58: 760–775.
40. Fleck MW, Henze DA, Barionouev G, Palmer AM (1993) Aspartate and glutamate mediate excitatory synaptic transmission in area CA1 of the hippocampus. J Neurosci 13: 3994–3995.
42. Ovanesov MV, Vogel MW, Moran TH, Pletnikov MV (2007) Neonatal Borna disease virus infection in rats is associated with increased extracellular levels of glutamate and neurodegeneration in the striatum. J Neurovirol 13: 185–194.
43. Ludwig H, Furuya K, Bode L, Klein N, Durrwald R, et al. (1993) Biology and neurobiology of Borna disease viruses (BDV), defined by antibodies, neutralizability and their pathogenic potential. Arch Virol Suppl 7: 111–133.
44. de la Torre JC, Bode L, Durrwald R, Cubitt B, Ludwig H (1996) Sequence characterization of human Borna disease virus. Virus Res 44: 33–44.
45. Y Benjamini Y, Yekutieli D (2001) The control of the false discovery rate in multiple testing under dependency. Ann.Statist 29: 1165–1188.
46. Mashego MR, Rumbold K, De Mey M, Vandamme E, Sotaert W, et al. (2007) Microbial metabolomics: past, present and future methodologies. Biotechnol Lett 29: 1–16.